Innate Pharma présente des données préliminaires de l'essai TELLOMAK montrant une réponse clinique avec lacutamab dans le mycosis fungoides
22 juin 2021 07h00 HE
|
INNATE PHARMA
Marseille, 22 juin 2021 (GLOBE NEWSWIRE) -- Les premières données cliniques de TELLOMAK établissent la sécurité de lacutamab, des réponses cliniques ainsi qu’une amélioration au niveau de la peau...
Innate Pharma presents preliminary data from TELLOMAK trial showing clinical response for lacutamab in mycosis fungoides
22 juin 2021 07h00 HE
|
INNATE PHARMA
Marseille, June 22, 2021 (GLOBE NEWSWIRE) -- First data set from TELLOMAK establishes safety, clinical responses and skin improvement in patients with mycosis fungoides that express KIR3DL2 Data...
Innate Pharma to Host Key Opinion Leader Discussion on the Potential Role of Lacutamab Across T-Cell Lymphomas
03 févr. 2021 01h00 HE
|
INNATE PHARMA
MARSEILLE, France, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that it will host a virtual...
INNATE PHARMA RECEIVES PRIME DESIGNATION FROM THE EUROPEAN MEDICINES AGENCY FOR LACUTAMAB IN SÉZARY SYNDROME
13 nov. 2020 01h00 HE
|
INNATE PHARMA
Marseille, France, Nov. 13, 2020 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) ("Innate" or the "Company") today announced that the European Medicines...
INNATE PHARMA REÇOIT LE STATUT « PRIME » DE L’AGENCE EUROPÉENNE DU MÉDICAMENT POUR LACUTAMAB DANS LE SYNDROME DE SÉZARY
13 nov. 2020 01h00 HE
|
INNATE PHARMA
Marseille, France, 13 nov. 2020 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris : IPH – ISIN : FR0010331421 ; Nasdaq : IPHA) (« Innate » ou la « Société ») a annoncé que l’Agence Européenne...
U.S. Food and Drug Administration Lifts Partial Clinical Hold on Lacutamab TELLOMAK Trial in Advanced T-Cell Lymphomas
24 juin 2020 01h00 HE
|
INNATE PHARMA
Innate Pharma to re-activate TELLOMAK trial in the US New GMP-certified batch has been successfully manufactured Conference call to be held today on the lacutamab clinical trial program ...